Minnie M Sarwal, MD
Pediatric Medicine · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 2
Offices
2 locations · UCSF Medical Group Business Services · UCSF Dept of Surgery
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sarwal’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A70504 · Current
Licensed to practise in California · since 1999 · expires 2027-07-31 · University of Calcutta Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$6,820
Medicare paid this office $6,820 for 43 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 35 | $5,522 | $104 |
Who their Medicare patients are
43 Original Medicare patients in 2024. Average age 55 · Under 65 67% · Women 42% · Also on Medicaid 61% · Health risk score 5.04. Sicker patients than 9 in 10 peers; the typical pediatric medicine clinician is at 1.4.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 75% · Coronary heart disease 33% · Depression 26%.
The office billed $50,144, Medicare allowed $10,220 and paid $6,820; for 69 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 43 | 69 | 55 | 5.04 | $50,144 | $6,820 |
| 2023 | 43 | 66 | 53 | 5.66 | $48,746 | $6,912 |
| 2022 | 44 | 74 | 50 | 3.75 | $47,443 | $7,377 |
| 2021 | 57 | 97 | 51 | 3.88 | $51,170 | $8,223 |
| 2020 | 55 | 96 | 51 | 4.46 | $61,226 | $7,880 |
| 2019 | 52 | 63 | 53 | 5.02 | $47,558 | $6,157 |
| 2018 | 23 | 30 | 51 | 3.81 | $21,281 | $2,544 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 28 | $4,516 | $113 |
| Return visit (30+ min) | 15 | $1,248 | $73 |
2022: 2 services
| Long return visit (40+ min) | 21 | $3,022 | $126 |
| Return visit (30+ min) | 22 | $2,129 | $82 |
2021: 2 services
| Return visit (30+ min) | 36 | $4,137 | $86 |
| Long return visit (40+ min) | 14 | $2,120 | $133 |
2020: 2 services
| Long return visit (40+ min) | 30 | $3,306 | $94 |
| Return visit (30+ min) | 27 | $2,660 | $70 |
2019: 2 services
| Long return visit (40+ min) | 25 | $3,386 | $100 |
| Return visit (30+ min) | 11 | $782 | $71 |
2018: 1 service
| Long return visit (40+ min) | 15 | $1,974 | $94 |
Drugs they prescribed that Part D paid
$8,600
Pharmacies billed $8,600 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 134) in 2024. At or below the middle of the specialty; the typical pediatric medicine clinician is at 0%.
131 generic and fewer than 11 brand-name prescriptions · $8,600 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Midodrine | 13 | $308 | $24 |
| Prednisone | 34 | $236 | $7 |
| Losartan | 12 | $67 | $6 |
Year by year
| 2024 | 134 | 25 | 0% (0) | None | $8,600 |
| 2023 | 67 | 24 | 0% (0) | None | $6,379 |
| 2022 | 137 | 24 | 0% (0) | None | $54,226 |
| 2021 | 102 | 23 | 0% (0) | 16% | $5,154 |
| 2020 | 47 | 19 | 0% (0) | None | $1,293 |
| 2019 | 28 | None | 0% (0) | 0% | $2,107 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 2 drugs
| Rosuvastatin | 13 | $686 | $53 |
| Prednisone | 11 | $127 | $12 |
2021: 2 drugs
| Furosemide | 11 | $77 | $7 |
| Atorvastatin | 11 | $16 | $1 |
2020: 1 drug
| Amlodipine Besylate | 11 | $94 | $9 |
Money from drug and device companies
$3,464 in 2023
| 2023 | 1 | 1 | $3,464 | $3,464 |
| 2022 | 1 | 1 | None | $20 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| CSL Behring | None | $3,464 | 1 payment
|
See the published payment
| CSL Behring | Consulting · 2023-01-10 | None | $3,464 |
See earlier years (2022)
2022: $20
| Gilead Sciences | None | $20 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| E.R. Squibb & Sons, L.L.C. · 59464 Best Sty Prop Sub Studies Min Invasive Diag of Acute Rej and New Onset of Diab Mel After Transplant Nodat in Kdy Transplant Best Sub Sty · 2022 | Their institution | $8,000 |
| Genentech, Inc. · A Multi-Center, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive Iga Nephropathy Supplemental Genomic Analysis To Evaluate Molecular Mechanisms for Treatment Efficacy and Outcomes · 2019 | Their institution | $2,000 |
Professional record
- NPI
- 1235151218
- Licence
- CA A70504California A70504: Current · expires 2027-07-31
- Group
- UCSF Medical Group Business Services · UCSF Dept of Surgery
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0210X (2080P0210X)
- Mailing address
- 305 Willowbrook Dr, Portola Valley, CA, 94028
- NPI first listed
- 2006-07-25
- NPI last updated
- 2012-01-04
This is when the NPI record was last certified, not a medical board exam.